Sapropterin Teva 100 mg Norvège - norvégien - Statens legemiddelverk

sapropterin teva 100 mg

teva gmbh - sapropterindihydroklorid - oppløselig tablett - 100 mg

Champix Union européenne - norvégien - EMA (European Medicines Agency)

champix

pfizer europe ma eeig - vareniklin - tobakk bruk stopp - andre nervesystemet narkotika - champix er indisert for røykeslutt hos voksne.

Cefotaxim Navamedic 0.5 g Norvège - norvégien - Statens legemiddelverk

cefotaxim navamedic 0.5 g

navamedic asa - cefotaksimnatrium - pulver til injeksjonsvæske, oppløsning - 0.5 g

Cefotaxim Navamedic 1 g Norvège - norvégien - Statens legemiddelverk

cefotaxim navamedic 1 g

navamedic asa - cefotaksimnatrium - pulver til injeksjonsvæske, oppløsning - 1 g

Cefotaxim Navamedic 2 g Norvège - norvégien - Statens legemiddelverk

cefotaxim navamedic 2 g

navamedic asa - cefotaksimnatrium - pulver til injeksjonsvæske, oppløsning - 2 g

Enalapril Krka 5 mg Norvège - norvégien - Statens legemiddelverk

enalapril krka 5 mg

krka sverige ab - enalaprilmaleat - tablett - 5 mg

Enalapril Krka 10 mg Norvège - norvégien - Statens legemiddelverk

enalapril krka 10 mg

krka sverige ab - enalaprilmaleat - tablett - 10 mg

Enalapril Krka 20 mg Norvège - norvégien - Statens legemiddelverk

enalapril krka 20 mg

krka sverige ab - enalaprilmaleat - tablett - 20 mg

Ferglep vet 200 mg/ ml Norvège - norvégien - Statens legemiddelverk

ferglep vet 200 mg/ ml

laboratories hipra s.a. - gleptoferron - injeksjonsvæske, oppløsning - 200 mg/ ml

Cabometyx Union européenne - norvégien - EMA (European Medicines Agency)

cabometyx

ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - antineoplastiske midler - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.